Elevated serum plasminogen activator inhibitor-1 is associated with seizure burden, drug resistance, and neuroinflammatory markers in pediatric epilepsy - Summary - MDSpire
Advertisement
Elevated serum plasminogen activator inhibitor-1 is associated with seizure burden, drug resistance, and neuroinflammatory markers in pediatric epilepsy
To investigate the association of PAI-1 with neuroinflammation, seizure susceptibility, and clinical outcomes in pediatric epilepsy patients.
Approach:
Study Design: A case-control study involving 200 pediatric epilepsy patients and 100 healthy controls.
Data Collection: Serum levels of PAI-1, cytokines, and markers of BBB disruption were quantified using ELISA. Clinical data on seizure frequency and treatment response were collected.
Statistical Analysis: Statistical methods included t-tests, ANOVA, Pearson correlation, multivariate linear regression, and ROC analysis.
Key Findings:
Serum PAI-1 levels were significantly higher in epilepsy patients compared to controls (28.47 ± 12.10 ng/mL vs. 11.35 ± 5.05 ng/mL; p < 0.001).
PAI-1 levels correlated positively with seizure frequency (r = 0.537, p < 0.001) and were higher in drug-resistant epilepsy patients (p < 0.001).
PAI-1 demonstrated excellent diagnostic performance for epilepsy (AUC = 0.916).
PAI-1 levels correlated with neuroinflammatory markers (IL-6: r = 0.270, p < 0.001) and BBB disruption (S100B: r = 0.271, p < 0.001).
Higher PAI-1 levels were associated with poorer quality of life scores (r = −0.227, p < 0.001).
Interpretation:
PAI-1 is significantly elevated in pediatric epilepsy and correlates with seizure burden, neuroinflammation, BBB disruption, drug resistance, and quality of life.
Limitations:
The study is cross-sectional, limiting causal inferences.
Longitudinal studies are needed to assess the predictive value of PAI-1 over time.
Conclusion:
PAI-1 may serve as a risk-stratification biomarker for identifying children with higher disease burden and potential treatment resistance.
